Q1 2024 · 13F-HR
Commodore Capital LPholdings as filed
Filed 2024-05-15 · accession 0001831942-24-000006
$1.50B
Reported value
39
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N5749R100 | 2GH | MERUS N V | $196.3M | 13.1% | 4,360,000 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $136.5M | 9.13% | 3,165,000 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $111.7M | 7.47% | 1,487,756 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $93.3M | 6.24% | 2,167,793 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $71.5M | 4.78% | 1,884,084 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $69.9M | 4.67% | 3,973,245 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $58.7M | 3.93% | 860,000 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $54.8M | 3.67% | 5,833,333 | Common | SOLE |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $54.5M | 3.64% | 1,375,000 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $52.6M | 3.52% | 1,275,000 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $45.5M | 3.04% | 1,050,000 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $43.2M | 2.89% | 6,425,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $39.9M | 2.67% | 1,725,000 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $36.4M | 2.43% | 866,468 | Common | SOLE |
| 65487U108 | NKTX | NKARTA INC | $34.2M | 2.29% | 3,165,000 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $33.9M | 2.27% | 1,934,653 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $33.6M | 2.25% | 1,555,954 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $32.5M | 2.18% | 1,525,000 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS INC | $27.9M | 1.86% | 3,410,384 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $27.5M | 1.84% | 2,000,000 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $27.1M | 1.81% | 1,895,003 | Common | SOLE |
| 46489V104 | ISREUR | PERSPECTIVE THERAPEUTICS INC | $25.1M | 1.68% | 21,052,631 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $24.3M | 1.62% | 750,990 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $22.7M | 1.52% | 912,189 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $21.2M | 1.42% | 1,250,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $19.3M | 1.29% | 290,000 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $18.8M | 1.25% | 1,100,000 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $14.7M | 0.98% | 2,300,000 | Common | SOLE |
| 88427A107 | — | THIRD HARMONIC BIO INC | $11.8M | 0.79% | 1,250,000 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $10.2M | 0.68% | 200,000 | Common | SOLE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $9.3M | 0.62% | 657,333 | Common | SOLE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $8.3M | 0.56% | 1,575,000 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $7.6M | 0.51% | 318,851 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $7.3M | 0.49% | 169,533 | Common | SOLE |
| G4444H101 | BBOT | HELIX ACQUISITION CORP II | $5.2M | 0.35% | 500,000 | Common | SOLE |
| 556099109 | MGNX | MACROGENICS INC | $4.3M | 0.29% | 295,020 | Common | SOLE |
| 007002108 | TORCEUR | ADICET BIO INC | $3.2M | 0.22% | 1,374,320 | Common | SOLE |
| 78397T202 | SABS | SAB BIOTHERAPEUTICS INC | $831,610 | 0.06% | 183,174 | Common | SOLE |
| 23306J101 | — | DBV TECHNOLOGIES S A | $69,432 | 0.00% | 92,687 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.